ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings

July 25, 1986

House subcommittee’s 5.6% Increase For NIH includes $2.5 Billion for NCI

July 18, 1997

In Brief: AACR To Have Fur Symposia, Including One With ASCO; McConnell Names TRTP Director

March 21, 1986

IOM, NCI Clash Over Proposed Change in Tabulating Minority Research

January 22, 1999

Research teams link response to Iressa to mutations in EGF receptor.

April 30, 2004

Research Funding: Clinton Proposes 2.6% Increase For NIH, Amount Called “Paltry”

February 14, 1997